Generic Name and Formulations:
Retapamulin 1%; oint.
Indications for ALTABAX:
Topical treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes in patients ≥9 months of age.
Adults and Children:
<9 months: not recommended. ≥9 months: apply thin layer to affected area (up to 100cm2 in total area in adults or 2% total body surface area in children) twice daily for 5 days. May cover with bandage or gauze dressing. Reevaluate if no improvement in symptoms within 3–4 days after starting treatment.
Not for intraoral, intranasal, ophthalmic, or intravaginal use. Discontinue if irritation or sensitization occurs. Prolonged use may result in superinfection. Pregnancy (Cat.B). Nursing mothers.
Application site irritation.
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd